Solid Biosciences Inc. (SLDB) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Pardon me, this is the operator. Today's conference is scheduled to begin shortly. Please continue to stand by and thank you for your patience. Thank you. Thank you. Ladies and gentlemen, thank you for standing by, and welcome to the Solid Biosciences Strategic Business Update and Financial Results Conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference may be recorded. After the presentation, there will be a question-and-answer session. To ask a question, please press star 1 on your telephone to get in the queue. I would now like to hand the conference over to Caitlin Lowy, Vice President of Communications and Investor Relations at Solid Biosciences. Ms. Lowy, you may begin. Good morning. Thank you, Operator. Before we get started, I would like to remind everyone that during today's conference call, we may make forward-looking statements, including statements about the company's financial results, financial guidance, future business strategies and operations, and product development and regulatory progress, including statements about the company's Ignite DMV clinical trial. Actual results could differ material from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic, and other risks described in the risk factors section of our most recently filed annual report on Form 10-K and other periodic reports filed with the SEC. We undertake no obligation to update any forward-looking statements after the date of this call. With me on today's call are Ilan Ganote, Co-Founder, President, and Chief Executive Officer of Solid Biosciences,...